SAN Sanofi

Regeneron and Sanofi (NASDAQ:SNY) announced an expanded collaboration focused on developing next-generation medicines for type 2 inflammatory diseases, extending an alliance that has produced the blockbuster therapy DUPIXENT. Under the agreement, Regeneron will contribute four long-acting, fully hu

The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.

Investing.com -- Shares of Sanofi jumped as much as 3.6% on Thursday before paring gains to trade 1.1% higher after the French drugmaker agreed to pay Regeneron $1 billion upfront and up to $7 billion in additional payments to expand their partnership on four long-acting medicines for inflammatory diseases.

The liquidation auctioneer Liquidity Services is closing in on a buy point. The stock is up roughly 45% this year.

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

SNY's new drugs are gaining momentum, with Altuviiio, Ayvakit and Sarclisa poised to broaden growth beyond Dupixent.

Sanofi (ENXTPA:SAN) opened the Charles Best Building in Canada, described as the largest biomanufacturing investment in the country. The new Canadian site expands Sanofi's flu vaccine production capacity, with the goal of strengthening readiness for future influenza seasons. Sanofi agreed to transfer a portfolio of mature medicines and several manufacturing sites to Cheplapharm, while also taking an equity stake in the partner. The inauguration of the Charles Best Building and the broadened...

Amgen Inc (NASDAQ:AMGN, XETRA:AMG)'s price target was raised to $410 from $367 by Jefferies after dazodalibep delivered positive Phase 3 results in patients with systemic Sjögren's disease. Jefferies said the drug, a CD40L antagonist, achieved a statistically significant and clinically...

European equities traded in the US as American depositary receipts were tracking lower Wednesday mor

All the chairs of Europe’s big pharma companies have written a public letter asserting that a shift in strategy is needed to close the gap to international rivals.

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Britain’s biggest pharmaceutical companies have warned the future of the industry is at risk as Europe loses ground to the US and China in medical research.

LONDON, Sept 22 (Reuters) - European drugmakers called for beefed-up government spending on medicines, faster trials and IP protections as they sounded warnings ‌on Tuesday that the continent's pharmaceutical industry risks losing out to the ‌United States and China. Cash-strapped European governments have been under pressure for some time from lobby groups ​and drugmakers to rethink how they attract, nurture, value and pay for innovative medicines to avoid falling behind in an increasingly com

Sanofi (NASDAQ:SNY) is reviewing its late-stage pipeline, broadening its business-development lens and working to rebuild early research output under new leadership, Chief Scientific Officer and Global Head of Research Mike Quigley said at a Bank of America event. Quigley said Chief Executive Offic

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company’s shift toward an end-to-end, AI-enabled drug discovery and development platform. Kha

Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the company’s executive vice president and head of Specialty Care. Speaking at a Morgan Stanley fireside ch

Investing.com -- European assets may offer investors advantages that are being overlooked as markets remain heavily focused on U.S. technology leadership, according to Macquarie Global Strategy, which sees structural changes supporting stronger European returns.

Healthcare stocks were slightly lower late Wednesday afternoon, with the NYSE Healthcare Index fract

Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad institutional audience. Around the same time, bipartisan lawmakers introduced the Protecting Approved Care Act, stirring concern across healthcare names like Novavax about potential changes to Medicare Advantage reimbursement practices and administrative requirements. We’ll now examine how...

Sanofi has delivered mixed returns over recent years, and with the share price around €75.43, the real issue for you is whether that level is justified by the earnings power the group is producing today. Over the past 3 years, the stock has declined about 14.8%, which puts the spotlight on whether the current valuation is still aligned with the profits the business is generating. The planned transfer of 20 mature medicines and three manufacturing sites to Cheplapharm, in exchange for a 26.4%...

Under the proposed arrangement, Sanofi will receive a 26.4% equity stake in Cheplapharm.

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference. Marion McCourt, Regeneron’s EVP and head of commercial, said Dupixent’s growth